Consequently, Bansal believes that Pfizer’s stock should be held as it is not expected to outperform or underperform significantly in the near future. Bansal covers the Healthcare sector, focusing ...
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday. Shares of Pfizer Inc PFE rose during ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Pfizer (PFE – Research Report). The associated price target ...
Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...
The company also recently reported positive phase 2 results for ponsegromab, a potential medicine for cancer cachexia -- ...
We recently compiled a list of the 8 Best Wide Moat Stocks to Buy According to Analysts. In this article, we are going to ...
PFE trades at 11.2-times our 2025 EPS estimate, compared to an average of 23.0 for our coverage universe of large-cap biopharma stocks. Thus, if we assume that Pfizer will indeed beat the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback